OptiNose (OptiNose) Additional Paid-In Capital : $633.74 Mil(As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is OptiNose Additional Paid-In Capital?

OptiNose's quarterly additional paid-in capital increased from Jun. 2023 ($631.43 Mil) to Sep. 2023 ($632.77 Mil) and increased from Sep. 2023 ($632.77 Mil) to Dec. 2023 ($633.74 Mil).

OptiNose's annual additional paid-in capital increased from Dec. 2021 ($588.29 Mil) to Dec. 2022 ($628.24 Mil) and increased from Dec. 2022 ($628.24 Mil) to Dec. 2023 ($633.74 Mil).

OptiNose Additional Paid-In Capital Historical Data

The historical data trend for OptiNose's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptiNose Additional Paid-In Capital Chart

OptiNose Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

489.57

534.59

588.29

628.24

633.74

OptiNose Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															628.24	629.93	631.43	632.77	633.74

OptiNose Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

OptiNose Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of OptiNose's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

OptiNose (OptiNose) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (NAS:OPTN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

0OP:Germany

Address

1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067

Website

https://www.optinose.com

OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.

Executives

Marino Michael F Iii	officer: Chief Legal Officer & Corp Sec	C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Ramy A Mahmoud	officer: President & COO	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Peter K Miller	director, officer: Chief Executive Officer	C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087
Mvm Partners, Llc	10 percent owner	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Michele Janis	officer: Acting Chief Financial Officer	1020 STONY HILL ROAD, YARDLEY PA 19067
Victor M Clavelli	officer: Chief Commercial Officer	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Paul Jr. Spence	officer: Chief Commercial Officer	1507 POWNAL DRIVE, YARDLEY PA 19067
Anthony J Krick	officer: Chief Accounting Officer	1020 STONY HILL ROAD, YARDLEY PA 19067
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Kyle Dempsey	director	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Eric Bednarski	director	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Partners Llp Mvm	10 percent owner	30 ST. GEORGE STREET, LONDON X0 W1S SFH
Keith A. Goldan	officer: Chief Financial Officer	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Joseph C Scodari	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080